Summary
Global Markets Direct’s, ‘NewLink Genetics Corporation - Product Pipeline Review - 2016’, provides an overview of the NewLink Genetics Corporation’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by NewLink Genetics Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of NewLink Genetics Corporation
- The report provides overview of NewLink Genetics Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses NewLink Genetics Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features NewLink Genetics Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate NewLink Genetics Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for NewLink Genetics Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding NewLink Genetics Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
NewLink Genetics Corporation Snapshot 6
NewLink Genetics Corporation Overview 6
Key Information 6
Key Facts 6
NewLink Genetics Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
NewLink Genetics Corporation - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
NewLink Genetics Corporation - Pipeline Products Glance 15
NewLink Genetics Corporation - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
NewLink Genetics Corporation - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
NewLink Genetics Corporation - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
NewLink Genetics Corporation - Drug Profiles 20
algenpantucel-L 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
indoximod 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
tergenpumatucel-L 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
dorgenmeltucel-L 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Cellular Immunotherapy for Hormone Refractory Prostate Cancer 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Cellular Immunotherapy for Metastatic Renal Cell Carcinoma 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
influenza [strain A/H5N1] vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
influenza [strain A/H7N9] vaccine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
influenza [strain H1N1] vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit IDO and TDO for Cancer 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit TDO for Cancer 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
(arenavirus + yellow fever) vaccine 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Zika virus vaccine 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NewLink Genetics Corporation - Pipeline Analysis 37
NewLink Genetics Corporation - Pipeline Products by Target 37
NewLink Genetics Corporation - Pipeline Products by Route of Administration 38
NewLink Genetics Corporation - Pipeline Products by Molecule Type 39
NewLink Genetics Corporation - Pipeline Products by Mechanism of Action 40
NewLink Genetics Corporation - Recent Pipeline Updates 41
NewLink Genetics Corporation - Dormant Projects 49
NewLink Genetics Corporation - Company Statement 50
NewLink Genetics Corporation - Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53
List of Tables
NewLink Genetics Corporation, Key Information 6
NewLink Genetics Corporation, Key Facts 6
NewLink Genetics Corporation - Pipeline by Indication, 2016 8
NewLink Genetics Corporation - Pipeline by Stage of Development, 2016 10
NewLink Genetics Corporation - Monotherapy Products in Pipeline, 2016 11
NewLink Genetics Corporation - Combination Treatment Modalities in Pipeline, 2016 12
NewLink Genetics Corporation - Out-Licensed Products in Pipeline, 2016 13
NewLink Genetics Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 14
NewLink Genetics Corporation - Phase III, 2016 15
NewLink Genetics Corporation - Phase II, 2016 16
NewLink Genetics Corporation - Phase I, 2016 17
NewLink Genetics Corporation - Preclinical, 2016 18
NewLink Genetics Corporation - Discovery, 2016 19
NewLink Genetics Corporation - Pipeline by Target, 2016 37
NewLink Genetics Corporation - Pipeline by Route of Administration, 2016 38
NewLink Genetics Corporation - Pipeline by Molecule Type, 2016 39
NewLink Genetics Corporation - Pipeline Products by Mechanism of Action, 2016 40
NewLink Genetics Corporation - Recent Pipeline Updates, 2016 41
NewLink Genetics Corporation - Dormant Developmental Projects,2016 49
NewLink Genetics Corporation, Other Locations 51
NewLink Genetics Corporation, Subsidiaries 51
List of Figures
NewLink Genetics Corporation - Pipeline by Top 10 Indication, 2016 8
NewLink Genetics Corporation - Pipeline by Stage of Development, 2016 10
NewLink Genetics Corporation - Monotherapy Products in Pipeline, 2016 11
NewLink Genetics Corporation - Out-Licensed Products in Pipeline, 2016 13
NewLink Genetics Corporation - Pipeline by Target, 2016 37
NewLink Genetics Corporation - Pipeline by Route of Administration, 2016 38
NewLink Genetics Corporation - Pipeline by Molecule Type, 2016 39
NewLink Genetics Corporation - Pipeline Products by Mechanism of Action, 2016 40
